Sopharma AD (the “Company”) announces that on 3 November 2014 the Company bought 500 000 shares from the capital of Medika AD. After this transaction, the share of Sopharma AD in the capital of Medika AD increased to 19, 22%.

Sopharma AD (the “Company”) announces that on 4 November 2014 the Company bought 400 010 shares from the capital of Medika AD. After this transaction, the share of Sopharma AD in the capital of Medika AD increased to 23.20%.

Sopharma AD (the “Company”) hereby notifies all shareholders of the Company, that, as stated in the Invitation, the Annual General Meeting, convened by the Board of Directors for 21 June 2013 at 11:00 will take place for a first year at Sopharma Business Towers, Building B, floor 3, 5 Lachezar Stanchev Str.. The registration begins at 9:30 until 11:00.

Sopharma AD (the “Company”) notifies that for October 2014 the Company recorded an increase of sales revenues of 4% compared to the same month of 2013, including 12% increase of domestic sales and 1% increase of export sales. During the past ten months Sopharma AD recorded a decrease of sales revenues of 4%, including 4% increase of domestic sales and 7% decrease of export sales compared to the same period of 2013

SOPHARMA AD (the “Company”) hereby informs that from 13 June 2013 up to and including 19 June 2013 the Company bought 70285 own shares representing 0.053% of the share capital of the Company, to the total value of BGN 219399.15 on the Bulgarian Stock Exchange. The average price per share was BGN 3.12.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 4395372, representing 3.33% of the share capital of the Company.

SOPHARMA AD hereby informs that from 30 October 2014 up to and including 05 November 2014 the Company bought 1 000 own shares representing 0.0008% of the share capital of the Company, to the total value of 3 900 BGN on the Bulgarian Stock Exchange, the average price per share was 3.90 BGN. The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 107 052, representing 3.87% of the share capital of the Company.

Sopharma AD (the “Company”) notifies that on 7 November 2014 the Financial Supervision Commission approved the Contract for transformation through merger and two additional annexes to it, signed on 19 June 2014 between Sopharma AD, Sofia, UIC 831902088, hereinafter referred to as "Acquirer" and Bulgarian Rose – Sevtopolis AD, Kazanlak, UIC 123007916, hereinafter referred to as "Acquiree" in accordance with the requirements of art. 262d and following of the Commercial Act (CA).

Please be informed that the Annual General Meeting of shareholders of Sopharma AD, held on 21.06.2013 in Sofia, 5 Lachezar Stanchev str., took the following decisions:

SOPHARMA AD hereby informs that from 6 November 2014 up to and including 12 November 2014 the Company bought 2 100 own shares representing 0.0015% of the share capital of the Company, to the total value of 8 201.8 BGN on the Bulgarian Stock Exchange, the average price per share was 3.91 BGN. The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 109 152, representing 3.87% of the share capital of the Company.

SOPHARMA AD hereby informs that from 13 November 2014 up to and including 19 November 2014 the Company bought 300 own shares representing 0.0002% of the share capital of the Company, to the total value of 1109.8 BGN on the Bulgarian Stock Exchange, the average price per share was 3.70 BGN. The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 109 452, representing 3.87% of the share capital of the Company.